Elahere, an antibody-drug conjugate (ADC) that targets folate receptor alpha (FRα), has received full approval for the treatment of FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, ...

It’s worth noting that BMS’ decision to exit the deal comes shortly after AbbVie secured full FDA approval for its FRα-directed ADC candidate – Elahere (mirvetuximab soravtansine ...

ImmunoGen’s lead development programme was a folate receptor alpha (FRa)-targeted ADC, which ultimately became Elahere (mirvetuximab soravtansine). Elahere suffered multiple development setbacks ...

Among those successes is an ADC drug called Elahere (mirvetuximab soravtansine-gynx), which is indicated for FRa positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer.

Elahere (mirvetuximab soravtansine-gynx) is a brand-name injection that’s prescribed for certain types of cancer. As with other drugs, Elahere can cause side effects, such as eye problems, nerve ...

More than 55% of patients taking Elahere, an ovarian cancer approved in 2022, may experience vision loss, according to a new study. The FDA's label for Elahere (mirvetuximab soravtansine ...

Sutro Biopharma is a smaller ADC (antibody ... The impact of AbbVie's Elahere is misrepresented in my eyes, as NCCN guidelines recommend its use with Avastin in low and medium FRa expressors ...

The drug was initially approved for this indication under the accelerated pathway in 2022. A first-in-class antibody-drug conjugate (ADC), Elahere, was added to AbbVie’s portfolio earlier this year in ...

the most recent being Elahere for multiple gynecological tumors in 2022. With an estimated value around USD 10 Billion in 2023, witnessing 35% rise from the previous year, the global cancer ADC ...

Market open. AdCapital ( FRA:ADC ) Full Year 2023 Results Key Financial Results Revenue: €172.4m (up 11% from FY 2022). Net loss... You may think that with a price-to-sales (or "P/S") ratio of 0.1x ...

Mirvetuximab soravtansine demonstrated efficacy in heavily pretreated patients with FRα+, platinum-sensitive ovarian cancer, achieving a 51.9% objective response rate in the PICCOLO trial.